[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.70 -3.21% 81.40 81.40 82.00 82.40 81.40 81.60 1,432,015 16:26:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 33.2 370

Ekf Diagnostics Share Discussion Threads

Showing 3701 to 3724 of 3875 messages
Chat Pages: 155  154  153  152  151  150  149  148  147  146  145  144  Older
DateSubjectAuthorDiscuss
21/7/2021
08:00
wan, Current market forecasts certainly assume a surprising drop off in revenue, profit etc.
shanklin
21/7/2021
07:57
Another excellent trading update and confirmation that we are 'firmly' on course for the full year to be comfortably ahead of the already upgraded expectations. Given the managements conservative approach to forecasting and that the second half usually delivers a stronger performance compared to the first, it bodes well indeed for the full year outcome. And I am thus also very much looking forward to the managements delivery of the initial phases of EKF's 2021-2024 growth strategy.
wan
21/7/2021
07:09
Trading Update H1 2021 performance in-line with already upgraded management expectations Full year performance expected to be in-line with management expectations EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides the following trading update for the six months ended 30 June 2021. As previously announced in our AGM statement in May, the strong trading from the beginning of the year continued into the second quarter of 2021. This continues to reflect improving trading in the core business and ongoing strong demand for our contract manufacturing services for COVID-19 sample collection devices and associated kits. The Board remains confident that trading for the full year will remain strong and will be in-line with already materially upgraded management expectations. Revenues for the six months ended 30 June 2021 were GBP38.56m (H1 2020: GBP26.33m) and the Company expects to report adjusted EBITDA(1) in the region of GBP12.75m (H1 2020: GBP8.93m). Gross cash as at 30 June 2021 was GBP20.78m and cash net of borrowings was GBP20.39m, in-line with management expectations. In addition, the Company's interest in Renalytix plc (1,002,981 shares) had a fair value of GBP10.83m, and its Verici Dx plc securities (2,677,981 shares) had a fair value of GBP1.83m, based on closing mid-market prices on 30 June 2021. Following the payment of an inaugural cash dividend of 1p per share at the end of last year (in respect of 2019) the Company has confirmed its intention to maintain a modest but progressive dividend policy, and a further dividend payment to shareholders of 1.1p per ordinary share, which it proposes to pay on 1 December 2021 to shareholders on the register at the close of business on 5 November 2021. The ex-dividend date for this timetable is 4 November 2021. The Company remains confident that its growth strategy, as outlined to shareholders at the Annual General Meeting in May, will create a business which, aside from any COVID-19 related revenues, is capable of generating significant double-digit growth in adjusted EBITDA(1) over the next 3 to 4 years. The Board believe this can be achieved by: -- investing in the existing core business to drive strong organic growth; -- maximising value from the agreement with Mount Sinai Innovation Partners; -- seeking complementary and targeted earnings-enhancing acquisitions with key strategic value to the core business; -- continuing to maximise the opportunity to assist clients to control the impact of COVID-19, and to evolve new contract manufacturing capabilities in this area to a broader range of diagnostic and other healthcare settings. EKF expects to announce its unaudited results for the six months ended 30 June 2021 in the first half of September 2021, with the date to be confirmed in a subsequent announcement.
masurenguy
20/7/2021
08:55
A healthy opportunity? James Hester 18 hours ago While the coronavirus pandemic has put a huge spotlight on investment opportunities in the healthcare sector, it may also be worth considering growth prospects for the industry beyond COVID-19. Over the past 18 months, healthcare has shown its critical role in testing, therapeutics, vaccines and patient care. However, performance across healthcare stocks has varied greatly. Some firms have seen huge rises in revenue to reflect the take-up of their coronavirus-related solutions, while others have seen a revenue slump as patients have deferred non-COVID treatment or hospitals and clinics have postponed many non-emergency procedures. The easing of lockdowns means the other treatment areas are back on track, even as companies with coronavirus solutions still find a market for their products and services: vaccinations mean the world is learning to live with the disease though eradication is some way off. At the same time, businesses that have developed solutions in response to COVID-19 may also be able to further capitalise on these efforts by deriving non-coronavirus products from the same platforms. Doing good Laurie Don, investment manager at Liontrust, points to companies such as ThermoFisher Scientific and PerkinElmer in the US, which have been heavily involved in coronavirus testing, where revenues from COVID-related areas have grown more than enough to offset falls in other parts of their businesses that were shut or experienced a significant slowdown amid the pandemic. “Over the coming years, as the world recovers from and moves beyond COVID, we expect healthcare companies to continue to do well by doing good,” says Don. He singles out Swiss pharmaceutical giant Roche, which has seen significant demand for its diagnostic machines during the pandemic and is set to continue to expand its global footprint in this area. “Even as levels of COVID-19 testing fall, these machines will be put to work to scan for other serious diseases where governments have been less keen to invest the initial outlay, such as tuberculosis or hepatitis C,” comments Don. With countries heavily scarred by the pandemic, governments and individuals may be keener than ever to take a more proactive stance in monitoring and preventing disease before it occurs. Full article - hTTps://capital.com/a-healthy-opportunity
wan
19/7/2021
14:01
Investor presentation this Thursday @ 10am - https://investegate.co.uk/genincode-uk-ltd/rns/investor-presentation/202107190700085854F/ Matthew Walls, CEO and Paul Foulger, CFO will provide a live investor presentation via the Investor Meet Company platform at 10am BST on Thursday, 22 July 2021. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet GENinCode plc via:hxxps://www.investormeetcompany.com/genincode-plc/register-investor
gocanes
19/7/2021
14:00
Cardiovascular disease company, focused on clinically-proven genomic precision testing products, to seek admission to AIM through an IPO GENinCode plc, the cardiovascular disease ("CVD") risk assessment company focused on predictive genetics for the prevention of cardiovascular disease, is delighted to announce its intention to seek admission of its issued and to be issued Ordinary Shares to trading on AIM, a market of the London Stock Exchange plc ("Admission"). On admission, the Company is expected to have a market capitalisation of approximately £42 million. The Company's product portfolio draws on genomic precision testing using polygenic (multiple-genes) technology, advanced molecular testing, genotyping and sequencing. Through a simple blood or saliva sample, the Company can analyse a patient's medical information and genetic variants associated with CVD to determine a Genetic Risk Score which is used for the subsequent assessment of a patient's cardiovascular disease risk. The Company also provides risk assessment for thrombosis (genetic predisposition to blood clotting). The Company's SITAB system, a proprietary software, bioinformatics and algorithmic platform with online cloud-based reporting, is used to process and record test results and genetic information using algorithms and artificial intelligence to assess a patient's risk of a cardiovascular event. SITAB reports results directly via a web portal to healthcare practitioners, cardiologists and physicians, in a user-friendly format. The current standard of care for primary prevention and assessment of the risk of CVD has been in use and largely unchanged for many years. It is based on risk assessment equations which evaluate 'classic' or 'traditional' cardiovascular risk factors such as age, gender, smoking, blood cholesterol levels and blood pressure among other factors for the onset of CVD. The equations enable physicians to categorise patients as being at low, moderate or high risk of a CVD event, usually over the subsequent 10-year period or sometimes using a 'lifetime' horizon from which the patient is then assessed for lifestyle changes or treatment. It is recognised that these 'classic' or 'traditional' risk assessments are imperfect with events not infrequently occurring in those individuals categorised at 'low' or 'intermediate' risk. The advent of genetic risk assessment for CVD is now able to help identify and reclassify those individuals traditionally categorised in the 'low' or 'intermediate' risk populations who are at higher genetic risk of a CVD event than their current standard of care risk assessment suggests. This enables earlier in life preventative measures to be adopted to lower the future risk of a CVD event. With CVD mortality levels continuing to rise globally, there is an increasing need for cardiologists to apply genetics to help advance patient prognosis and diagnosis to treat the onset of CVD. The Company's products combine predictive models of genetics and patient data using classic cardiovascular risk factors (CVRFs) and are designed to improve predictive capability and genetic risk assessment to provide a personalised and thereby tailored treatment pathway. Recent studies and scientific reports show the correlation between genetic load/burden and the onset of CVD. The Directors believe that GENinCode's technology is at the forefront of genetic risk assessment in the CVD space. The Company's key products are CE-Marked with the core products Cardio inCode and Thrombo inCode having IP protection in the major growth markets of Europe, the UK and the United States. The Company has now commenced its commercial expansion programme in Europe, the UK and the United States. On 28 April 2021, the Company announced a partnership to provide genetic testing from labs based at Royal Brompton and Harefield Hospitals. Following this, it was announced on 14 June 2021 that a product commercialisation agreement had been entered into with EVERSANA in the US. The Directors believe that the partnership with EVERSANA, a leading provider of global commercial services to the life science industry, will provide a significant opportunity for the Group to progress its commercialisation plans for the US. The Company's commercialisation strategy in the US is a significant part of GENinCode's long-term growth and commercial strategy. The Directors expect Cardio inCode to be reviewed by the FDA as a De Novo device. The Company submitted an initial application to the FDA in February 2021 for Breakthrough Device designation for its Cardio inCode product. The FDA review is ongoing with a decision expected in Q3 2021.
gocanes
19/7/2021
10:52
9 months and counting - still in sideways mode. Not worth committing capital (yet) to a lifeless stock UNLESS the market gives us the green light first. Hard as it is in practice - patience wins the day. Good week chaps (and chapesses).
tongosti
19/7/2021
08:13
As predicted, (unfortunately) PCR testing requirements will need to go into overdrive to cope - 4 hours ago - Covid test delays hamper England’s battle against new wave Public health leaders battling to contain a rising tide of Covid-19 infections in England are being hampered by delays in accessing and processing PCR tests, even as the country lifts its last pandemic restrictions. A surge in numbers seeking a test is expected after all remaining social restrictions were ended on Monday and self-isolation rules eased, in favour of regular testing, from August 16. The Department of Health and Social Care said testing and tracing was “saving lives every single day and stopping the spread of the virus by breaking chains of transmission and helping to control outbreaks wherever they exist”. Anyone who had Covid symptoms could book home-testing PCR kits “and more booking slots are made available at testing sites each day”. People familiar with the situation said NHS Test and Trace was ramping up laboratory operations and the Leamington Spa lab would eventually be able to process hundreds of thousands of Covid tests every day. It was also exploring options to increase capacity at other labs across the network, as well as commercial labs. Full story FT.com - hTTps://www.ft.com/content/e79bf9c9-894a-4556-abb8-8ffb350831b9
wan
16/7/2021
11:47
Cheers pireric, good to see Investec as the new joint brokers starting to earn their fees.
rivaldo
15/7/2021
08:00
The upcoming flu season, which unfortunately is likely to see a significant increase this year, combined with a continuing COVID-19 pandemic, and with many countries opening up and returning to the workplace etc, clinicians will need a 'safe', sensitive, reliable, and convenient way to detect common respiratory viruses and to differentiate cases of COVID-19 infection that do not involve flu A or flu B infection.
wan
15/7/2021
07:55
For what its worth, investec initiated today, 88p PT
pireric
15/7/2021
07:50
Update to Longhorns Main website page, including effective high-throughput point of care test for SARS-CoV-2, Influenza, and Multiplex testing and details of a 'universal' influenza vaccine - Universal Influenza pre-clinical data published in Vaccines The original FDA-cleared inactivation media proven effective for High Throughput and Point of Care SARS-CoV-2, Influenza, and Multiplex testing. PrimeStore® MTM is the original inactivating transport media. It is a patented, FDA cleared sample collection system for nucleic acid testing. It serves to inactivate RNA, mRNA and DNA pathogens (including SARS-Cov-2) for safer and faster collection. Containing an optimized chemical formulation, PrimeStore® MTM enables healthcare providers, vaccine and drug developers, laboratories, and assay developers to expand both highly sensitive point of care and molecular testing without subjecting workers to live infectious agents. We have recently introduced PrimeStore® ATM as another type of sample collection device that serves to optimize molecular testing and protect lab workers in the collection process. Longhorn Vaccines and Diagnostics invented the inactivating transport category in 2007 and worked closely with the US FDA to create the new category of class II device: Microbial Nucleic Acid Stabilization and Transport Device. All inactivating transport devices must be cleared by the US FDA and compare themselves to PrimeStore MTM. hTTps://lhnvd.com/ Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies Abstract: A universal influenza candidate vaccine that targets multiple conserved influenza virus epitopes from hemagglutinin (HA), neuraminidase (NA) and matrix (M2e) proteins was combined with the potent Army liposomal adjuvant (ALFQ) to promote induction of broad immunity to seasonal and pandemic influenza strains. The unconjugated and CRM-conjugated composite peptides formulated with ALFQ were highly immunogenic and induced both humoral and cellular immune responses in mice. Broadly reactive serum antibodies were induced across various IgG isotypes. Mice immunized with the unconjugated composite peptide developed antibody responses earlier than mice immunized with conjugated peptides, and the IgG antibodies were broadly reactive and neutralizing across Groups 1 and 2 influenza viruses. Multi-epitope unconjugated influenza composite peptides formulated with ALFQ provide a novel strategy for the development of a universal influenza vaccine. These synthetic peptide vaccines avoid the pitfalls of egg-produced influenza vaccines and production can be scaled up rapidly and economically. hTTps://static1.squarespace.com/static/5f7dde76e3d6f427822285d4/t/60eee989e0913b02847f4454/1626270090757/vaccines-09-00698.pdf
wan
15/7/2021
07:46
wan Not unhappy. Just expect companies to be consistent as to the timings of their routine TSs.
shanklin
15/7/2021
07:43
Amongst much more, the AGM Statement included the following - Strong trading continues into the second quarter 2021 and the Board is now confident that trading for the full year will be comfortably ahead of already upgraded management expectations. hTTps://www.ekfdiagnostics.com/agm-statement1.html So, that tells us quite a lot already.
wan
15/7/2021
07:22
Had been expecting a TS today based on previous ones on 14-Jul-20 and 15-Jul-19. Anybody any idea please as to if and when this is likely to be issued?
shanklin
14/7/2021
06:50
Delta is far more transmissible, even for those who have received two vaccine doses, which will unfortunately become ever clearer very soon. HMS Queen Elizabeth: Covid outbreak on Navy flagship By Jonathan Beale & Hazel Shearing BBC News Published 1 hour ago An outbreak of Covid-19 has been confirmed on the Royal Navy's flagship, HMS Queen Elizabeth. The BBC has been told there have been around 100 cases on the aircraft carrier, which is part way through a world tour. Several other warships in the fleet accompanying it are also affected. Defence Secretary Ben Wallace said all crew on the deployment had received two doses of a Covid-19 vaccine and the outbreak was being managed. hTTps://www.bbc.co.uk/news/uk-57830617
wan
13/7/2021
19:27
Thinking out loud maybe, but yeah I have got it wrong previously
senseibull
13/7/2021
19:14
You are trying to second guess the future - good luck with that
davr0s
13/7/2021
19:06
My thoughts are why would anyone who is double jabbed take a PCR test on advice (not legally obliged to) and open up a can of worms for themselves in terms of notifying others and isolating when immune etc.
senseibull
13/7/2021
11:41
Thanks Mirandaj. And, my reading is that there will be a greater emphasis on PCR testing from 16th August - How are the rules about close contacts changing in England? From 16 August, anyone in England who has had both their Covid jabs will no longer have to self-isolate if a close contact tests positive for Covid. When they are notified about their contact, NHS Test and Trace will ask if they are fully vaccinated. If so, they will be advised to take one PCR test as soon as possible to make sure they haven't been infected. As long as that test is negative, and they don't develop symptoms, they won't need to take further PCR tests. However, anyone who tests positive or develops symptoms will still need to self-isolate, regardless of their vaccination status. People who have a second vaccine dose close to 16 August will have to wait two weeks after the jab before following the new rules. This is to allow the vaccination to take full effect. hTTps://www.bbc.co.uk/news/explainers-54239922 Press release Self-isolation to be eased for fully vaccinated adults in step 4 From 16 August, double jabbed individuals and under 18s will no longer need to self-isolate if they are identified as a close contact of someone with COVID-19 Young people and double vaccinated individuals identified as close contacts will continue to be advised to take a PCR test, to detect the virus and variants of concern. Anyone who tests positive following the PCR test will still be legally required to self-isolate, irrespective of their vaccination status. hTTps://www.gov.uk/government/news/self-isolation-to-be-eased-for-fully-vaccinated-adults-in-step-4
wan
13/7/2021
11:12
https://www.gov.uk/government/news/new-megalab-opens-to-bolster-fight-against-covid-19
mirandaj
09/7/2021
07:49
Jeff Fischer Co-Founder, President Longhorn Vaccines and Diagnostics LLC 15 hrs ago Point of Care (POC) testing for sarscov2 and influenza will be a significant component in pcr testing for the foreseeable future. Thank you to the roche team for providing equipment and assays for validation. PrimeStore MTM now validated on all major POC PCR platforms #liat #cepheid #biofire #genmark providing safer workflow. hTTps://www.linkedin.com/posts/jeff-fischer-4162a6a_new-study-in-the-journal-of-applied-laboratory-activity-6818887635344363520-cT8P I am still watching point of care testing (POCT) developments and so is Luke Daum, Chief Scientific Officer and Executive VP at Longhorn Vaccines and Diagnostics, who particularly follows and likes LumiraDx - hTTps://www.linkedin.com/posts/lumiradx_an-evaluation-of-the-detection-of-sars-cov-activity-6818208459155148800-vtkj The potential for PrimeStore ATM is why I am watching POCT development/evaluations etc. And fits well with EKF's rationale in providing the picks and shovels for Covid-19 testing.
wan
08/7/2021
09:40
I also posted recently that regular testing is expected to replace the disruptive self-isolation regime, and given the significant rise expected/forecast in infection rates over the next few months, testing volumes will likely increase accordingly......and probably significantly! To add weight to that view and strong possibility, the following frames it quite well - Business warns of England work chaos from delay to ending self-isolation Up to 2m people a week at risk as Sajid Javid’s lighter testing regime set for mid-August George Parker, John Burn-Murdoch and Oliver Barnes in London JULY 6 2021 Health secretary Sajid Javid admitted there could be a record 100,000 new Covid cases a day if most remaining restrictions are lifted on July 19 as planned. The projected number of daily cases would far exceed the 61,240 new daily cases when the virus peaked on January 1. But recent data show that a ratio of two people are asked to isolate for 10 days per original case, suggesting that if 700,000 a week were infected a further 1.4m could be asked to self-isolate. With cases doubling every nine days, Javid said the country was entering “uncharted territory” but that the “wall of protection” offered by coronavirus vaccines would allow new rules on self-isolation to apply from the middle of next month, arguing that death rates would remain low. He said any adult who had received both jabs would no longer have to self-isolate if they had been in close contact with a person who then tested positive for Covid-19. Contacts would be advised to take a PCR test and self-isolate if they tested positive. Those receiving a second dose around August 16 would need to wait two weeks for the vaccine to be fully effective. Full story FT.com - hTTps://www.ft.com/content/9883bfad-cc0c-4886-b830-3a2fdc692cbc And possibly more than one PCR test - 7th July 2021 What are the new self-isolating rules in England? From 16 August, anyone in England who is a close contact of someone who tests positive for Covid will no longer have to self-isolate if they've had both their jabs. When they are notified about their contact, the NHS Test and Trace app will ask if they are fully vaccinated. If so, they will be advised to take one PCR test as soon as possible to make sure they haven't been infected. As long as that test is negative, and they don't develop symptoms, they won't need to take further PCR tests. However, anyone who tests positive or develops symptoms will still need to self-isolate, regardless of their vaccination status. People who have a second vaccine dose close to 16 August will have to wait two weeks after the jab before following the new rules. This is to allow the vaccination to take full effect. hTTps://www.bbc.co.uk/news/explainers-54239922
wan
08/7/2021
09:29
Re: the above, I forgot that I posted previously (post 2092) That Mark Weaver, EKF Diagnostics Regional Sales Manager (Western Europe/ DACH) posted that PrimeStore MTM is being used routinely with Roche LIAT systems in the NHS. This ensures viral RNA integrity which minimises false negative results and keeps NHS staff safe! So, it appears that it is the preferred choice of the NHS, and rightly so!
wan
Chat Pages: 155  154  153  152  151  150  149  148  147  146  145  144  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210920 17:41:29